101. This title is unavailable for guests, please login to see more information.
- Author
-
NIIJIMA, Tadao, KOYANAGI, Tomohiko, MARU, Akio, SAKASHITA, Shigeo, KOISO, Kenkichi, ISHIKAWA, Hiromichi, UCHIDA, Katsunori, SHIMAZAKI, Jun, ISAKA, Shigeo, AKAZA, Hideyuki, MACHIDA, Toyohei, TASHIRO, Kazuya, NAKAGAMI, Yoshizo, LIN, Tsawtung, HOSAKA, Masahiko, KUBOTA, Yoshinobu, OBATA, Koji, KOBAYASHI, Hiroaki, SONODAM, Takao, MATSUDA, inoru, FUJIOKA, Hideki, KOTAKE, Toshihiko, KURODA, Masao, OHMORI, Hiroyuki, MATSUMURA, Yosuke, TSUSHIMA, Tomoyasu, UYAMA, Takeshi, KUMAZAWA, Joichi, UEDA, Toyofumi, OHI, Yoshitada, SHIMOINABA, Takao, NIIJIMA, Tadao, KOYANAGI, Tomohiko, MARU, Akio, SAKASHITA, Shigeo, KOISO, Kenkichi, ISHIKAWA, Hiromichi, UCHIDA, Katsunori, SHIMAZAKI, Jun, ISAKA, Shigeo, AKAZA, Hideyuki, MACHIDA, Toyohei, TASHIRO, Kazuya, NAKAGAMI, Yoshizo, LIN, Tsawtung, HOSAKA, Masahiko, KUBOTA, Yoshinobu, OBATA, Koji, KOBAYASHI, Hiroaki, SONODAM, Takao, MATSUDA, inoru, FUJIOKA, Hideki, KOTAKE, Toshihiko, KURODA, Masao, OHMORI, Hiroyuki, MATSUMURA, Yosuke, TSUSHIMA, Tomoyasu, UYAMA, Takeshi, KUMAZAWA, Joichi, UEDA, Toyofumi, OHI, Yoshitada, and SHIMOINABA, Takao
- Abstract
A phase II study of a new anthracycline anti-cancer antibiotics, epirubicin (EPI), was undertaken in 71 patients with urothelial malignancies; 40 with advanced urothelial malignancies and 31 with superficial bladder cancer. Out of them 32 patients with advanced stage of urothelial cancer were evaluated for the systemic use of EPI, while 30 patients with superficial bladder cancer for intravesical use. Intravenous administration of this new anticancer antibiotic, at a dosage of 60 mg/m2 every three weeks, showed the response rate of 20.0% for advanced bladder cancer and 14.3% for renal pelvic and ureteral tumors. In cases of superficial bladder cancer, at a dosage of 60 mg/30 ml X 3 day every week in principal, the response rate was 66.7%. Eight out of 30 patients showed complete disappearance of the tumor. Twelve patients also showed more than 50% tumor regression. As for adverse effects no serious cardiotoxicity was demonstrated. Anorexia and other gastrointestinal side effects, such as nausea and vomiting, were also seen. Alopecia and myelosuppression were the major adverse effects among patients with systemic EPI administration. With intravesical use of EPI, cystitis syndrome was the major toxicity. However, no systemic side effects were noted in these cases. In conclusion, EPI was assumed to be effective for the treatment of advanced urothelial tumors and superficial bladder cancer.
- Published
- 1986